Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-28T12:51:40.188Z Has data issue: false hasContentIssue false
  • English
  • Français

Agomelatine as adjunctive therapy in discontinuation of long-term benzodiazepine withdrawal

Published online by Cambridge University Press:  16 April 2020

H. Müller ,
P. Schütz ,
J.M. Maler  and
J. Kornhuber
H. Müller
Affiliation:
Psychiatry and Psychotherapy, University of Erlangen-Nürnberg, Erlangen, Germany
P. Schütz
Affiliation:
Psychiatry and Psychotherapy, University of Erlangen-Nürnberg, Erlangen, Germany
J.M. Maler
Affiliation:
Psychiatry and Psychotherapy, University of Erlangen-Nürnberg, Erlangen, Germany
J. Kornhuber
Affiliation:
Psychiatry and Psychotherapy, University of Erlangen-Nürnberg, Erlangen, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Agomelatine is a new antidepressive drug, that is successfully applied in therapy of insomnia and depression. Until now, there has been no report on its application as add-on medication in therapy for the withdrawl ob benzodiazepine.

We are reporting a case of a forty-year-old male patient who was treated with Agomelatine in lorazepam withdrawl therapy. He showed a considerabel reduction of craving as well as of insomnia and vegetative symptoms.

Therefore there is the question if the substance has its own anti-craving component and to what extent the melatonin-receptor profile is involved.

Type
P01-87
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 87
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.